Physician profile
Debabrata Bandyopadhyay
NPI 1942431135
$397,793.62
in general payments reported to CMS, 2019-2025
24 companies · $97K in 2025
The $97K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $22K · 2021: $72K · 2022: $79K · 2023: $77K · 2024: $51K · 2025: $97K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $137K · Consulting Fee: $39K · Honoraria: $25K · Travel and Lodging: $14K · Food and Beverage: $8,768 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $137,136.79 |
| Consulting Fee | $39,405.00 |
| Honoraria | $25,256.25 |
| Travel and Lodging | $14,026.17 |
| Food and Beverage | $8,768.17 |
| Education | $191.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $202,939.58 | 2019-2025 | Tyvaso, Orenitram, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155,931.31 | 2019-2025 | Ofev |
| Ani Pharmaceuticals, INC. | $31,427.81 | 2023-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $5,232.53 | 2019-2025 | Uptravi, Opsumit |
| Genentech, INC. | $690.56 | 2021-2023 | Pulmozyme |
| Mallinckrodt Hospital Products INC. | $296.41 | 2022-2024 | Acthar |
| Abiomed | $242.56 | 2022 | |
| Astellas Pharma US INC | $226.83 | 2021-2023 | Cresemba |
| Innovation Technologies INC | $173.86 | 2025 | Irrisept |
| Genentech USA, INC. | $137.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $93.76 | 2020-2022 | |
| Amgen INC. | $87.82 | 2024 | Tavneos |
| Paragonix Technologies, INC. | $64.90 | 2023 | Paragonix Lungguard Shipper, Paragonix Lungguard Sherpacool |
| Boston Scientific Corporation | $52.56 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Sandoz INC. | $42.00 | 2025 | Treprostinil |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.84 | 2023 | Livtencity |
| Vapotherm INC | $24.12 | 2023 | Vapotherm |
| Atricure, INC. | $19.50 | 2022 | |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Winrevair |
| Livanova USA, INC. | $15.43 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debabrata Bandyopadhyay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.